Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1997;30:1183-1190

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wiemer, G.
Right arrow Articles by Malinski, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wiemer, G.
Right arrow Articles by Malinski, T.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*High Blood Pressure
Hazardous Substances DB
*NITRIC OXIDE

(Hypertension. 1997;30:1183-1190.)
© 1997 American Heart Association, Inc.


Articles

Angiotensin-Converting Enzyme Inhibition Alters Nitric Oxide and Superoxide Release in Normotensive and Hypertensive Rats

Gabriele Wiemer; Wolfgang Linz; Stefan Hatrik; Bernward A. Schölkens; Tadeusz Malinski

From Hoechst Marion Roussel, DG Research Cardiovascular, Frankfurt/Main, Germany (G.W., W.L., B.A.S.); and the Department of Chemistry, Institute of Biotechnology, Oakland University, Rochester, Mich (S.H., T.M.).

Correspondence to Prof Tadeusz Malinski, Department of Chemistry, Institute of Biotechnology, Oakland University, Rochester, MI 48309-4401.

Abstract Young ({approx}1 month old) male normotensive Wistar-Kyoto rats (n=26) and spontaneously hypertensive rats (n=38) were randomized into three groups treated via drinking water for {approx}2 years with, respectively, placebo, low doses, or high doses of an angiotensin-converting enzyme inhibitor, ramipril (10 µg · kg-1 · d-1, non–blood pressure–lowering dose, or 1 mg · kg-1 · d-1, blood pressure–lowering dose). Relative to placebo treatment in each respective rat strain, both ramipril dosages increased endothelial constitutive nitric oxide synthase expression (Western blot) and resultant synthesis of nitric oxide (porphyrinic sensor) in freshly excised carotids and thoracic aortas, respectively. Paradoxically, this activity was associated with an increased/decreased superoxide accumulation (chemiluminescence) in freshly excised aortas from 24-/22-month-old normotensive/hypertensive rats. In normotensive rats, relative to placebo treatment, the threefold increase in superoxide accumulation with antihypertensive ramipril treatment is most likely from the >300% increase in endothelial constitutive nitric oxide synthase expression (some of which may be disarranged by local insufficiencies in L-arginine or tetrahydrobiopterin). In hypertensive rats, relative to placebo treatment, the 35% increase in nitric oxide availability by long-term antihypertensive ramipril treatment may contribute to the preservation of the endothelium and prevent its dysfunction by inhibiting superoxide production. Increased nitric oxide production with concomitant decreased superoxide accumulation (approximately one third of placebo levels) correlates positively with the previously reported +40% life span extension for rats with genetic hypertension that were treated with antihypertensive doses of ramipril.


Key Words: ramipril • nitric oxide • nitric oxide synthase-III • hypertension • aging • endothelium • superoxide




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Feletou and P. M. Vanhoutte
Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture)
Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H985 - H1002.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
T. S. Hermann, W. Li, H. Dominguez, N. Ihlemann, C. Rask-Madsen, A. Major-Pedersen, D. B. Nielsen, K. W. Hansen, M. Hawkins, L. Kober, et al.
Quinapril Treatment Increases Insulin-Stimulated Endothelial Function and Adiponectin Gene Expression in Patients with Type 2 Diabetes
J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 1001 - 1008.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
A. Schafer, D. Fraccarollo, P. Tas, I. Schmidt, G. Ertl, and J. Bauersachs
Endothelial dysfunction in congestive heart failure: ACE inhibition vs. angiotensin II antagonism
Eur J Heart Fail, March 1, 2004; 6(2): 151 - 159.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
W. Linz, G. Itter, L. W Dobrucki, T. Malinski, and G. Wiemer
Ramipril improves nitric oxide availability in hypertensive rats with failing hearts after myocardial infarction
Journal of Renin-Angiotensin-Aldosterone System, September 1, 2003; 4(3): 180 - 185.
[Abstract] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
N. Weckler, D. Leitzbach, L. Kalinowski, T. Malinski, A. E Busch, and W. Linz
Effect of chronic treatment with the vasopeptidase inhibitor AVE 7688 and ramipril on endothelial function in atherogenic diet rabbits
Journal of Renin-Angiotensin-Aldosterone System, September 1, 2003; 4(3): 191 - 196.
[Abstract] [PDF]


Home page
Cardiovasc ResHome page
A. Schafer, D. Fraccarollo, S. K Hildemann, P. Tas, G. Ertl, and J. Bauersachs
Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction
Cardiovasc Res, June 1, 2003; 58(3): 655 - 662.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
J. M. Forbes, M. E. Cooper, V. Thallas, W. C. Burns, M. C. Thomas, G. C. Brammar, F. Lee, S. L. Grant, L. A. Burrell, G. Jerums, et al.
Reduction of the Accumulation of Advanced Glycation End Products by ACE Inhibition in Experimental Diabetic Nephropathy
Diabetes, November 1, 2002; 51(11): 3274 - 3282.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. R. Brasier, A. Recinos III, and M. S. Eledrisi
Vascular Inflammation and the Renin-Angiotensin System
Arterioscler Thromb Vasc Biol, August 1, 2002; 22(8): 1257 - 1266.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
M. Rathaus and J. Bernheim
Oxygen species in the microvascular environment: regulation of vascular tone and the development of hypertension
Nephrol. Dial. Transplant., February 1, 2002; 17(2): 216 - 221.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
P.M. Vanhoutte
Ageing and endothelial dysfunction
Eur. Heart J. Suppl., February 1, 2002; 4(suppl_A): A8 - A17.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
J. Bauersachs, M. Heck, D. Fraccarollo, S. K. Hildemann, G. Ertl, M. Wehling, and M. Christ
Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: Role of vascular superoxide anion formation and endothelial nitric oxide synthase expression
J. Am. Coll. Cardiol., January 16, 2002; 39(2): 351 - 358.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
G. Wiemer, G. Itter, T. Malinski, and W. Linz
Decreased Nitric Oxide Availability in Normotensive and Hypertensive Rats With Failing Hearts After Myocardial Infarction
Hypertension, December 1, 2001; 38(6): 1367 - 1371.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. Munzel and J. F. Keaney Jr
Are ACE Inhibitors a "Magic Bullet" Against Oxidative Stress?
Circulation, September 25, 2001; 104(13): 1571 - 1574.
[Full Text] [PDF]


Home page
HypertensionHome page
J. M. A. van Ampting, M. L. Hijmering, J. J. Beutler, R. E. van Etten, H. A. Koomans, T. J. Rabelink, and E. S. G. Stroes
Vascular Effects of ACE Inhibition Independent of the Renin-Angiotensin System in Hypertensive Renovascular Disease : A Randomized, Double-Blind, Crossover Trial
Hypertension, January 1, 2001; 37(1): 40 - 45.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
H. Sumino, T. Nakamura, T. Kanda, K. Sato, T. Sakamaki, T. Takahashi, Y. Saito, J. Hoshino, T. Kurashina, and R. Nagai
Effect of Enalapril on Exhaled Nitric Oxide in Normotensive and Hypertensive Subjects
Hypertension, December 1, 2000; 36(6): 934 - 940.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
W. Linz, H. Heitsch, B. A. Scholkens, and G. Wiemer
Long-Term Angiotensin II Type 1 Receptor Blockade With Fonsartan Doubles Lifespan of Hypertensive Rats
Hypertension, April 1, 2000; 35(4): 908 - 913.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
J. Zicha and J. Kunes
Ontogenetic Aspects of Hypertension Development: Analysis in the Rat
Physiol Rev, October 1, 1999; 79(4): 1227 - 1282.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
W. Linz, P. Wohlfart, B. A Scholkens, T. Malinski, and G. Wiemer
Interactions among ACE, kinins and NO
Cardiovasc Res, August 15, 1999; 43(3): 549 - 561.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. Zanzinger
Role of nitric oxide in the neural control of cardiovascular function
Cardiovasc Res, August 15, 1999; 43(3): 639 - 649.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
W. Linz, P. Wohlfart, B. A. Schoelkens, R. H. A. Becker, T. Malinski, and G. Wiemer
Late Treatment With Ramipril Increases Survival in Old Spontaneously Hypertensive Rats
Hypertension, August 1, 1999; 34(2): 291 - 295.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Wassmann, U. Laufs, D. Stamenkovic, W. Linz, J.-P. Stasch, K. Ahlbory, R. Rosen, M. Bohm, and G. Nickenig
Raloxifene Improves Endothelial Dysfunction in Hypertension by Reduced Oxidative Stress and Enhanced Nitric Oxide Production
Circulation, April 30, 2002; 105(17): 2083 - 2091.
[Abstract] [Full Text] [PDF]